Correctsequence Therapeutics Co., Ltd
Clinical trials sponsored by Correctsequence Therapeutics Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene editing shot aims to tame deadly fat levels in rare disease Results expected Dec 2026 (estimated)
- Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises Results expected Dec 2026 (estimated)
-
Gene-Editing hope for thalassemia patients: early trial launched
Disease control By invitation onlyThis early-phase trial is testing a new gene therapy called CS-101 for people with beta-thalassemia, a blood disorder that often requires lifelong transfusions. The treatment uses the patient's own stem cells, which are modified in a lab to produce fetal hemoglobin, potentially r…
Early phase 1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Gene-edited cell therapy for beta-thalassemia: long-term safety check begins
Disease control By invitation onlyThis study follows 5 people with beta-thalassemia who already received an experimental gene-edited cell therapy called CS-101. Researchers will monitor them for years to see if the treatment remains safe and whether they can stay free from blood transfusions for at least 12 month…
Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
8 patients with β-thalassemia tracked for years after one-time cell therapy
Disease control By invitation onlyThis study follows 8 people with β-thalassemia who already received a one-time treatment called CS-101, which modifies their own blood cells to produce fetal hemoglobin. No new drug is given. Researchers will monitor them for years to see if they stay free of blood transfusions a…
Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC